First pass intestinal and liver metabolism of paracetamol in a microfluidic platform coupled with a mathematical modeling as a means of evaluating ADME processes in humans

Biotechnology and Bioengineering

Volumn 111, Issue 10, 2014, Pages 2027-2040

  Prot, Jean Matthieu ^a   Maciel, Luis ^a   Bricks, Thibault ^a   Merlier, Franck ^a   Cotton, Jérôme ^b   Paullier, Patrick ^a   Bois, Fréderic Yves ^a,c   Leclerc, Eric ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^b Profilomic   (France)

^c INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

Author keywords

Alternative methods; Caco 2; In vitro in vivo extrapolation; Liver microfluidic biochip; Paracetamol; Permeability; Pharmacokinetic model; Phase II metabolism

Indexed keywords

BIOCHIPS; MATHEMATICAL MODELS; MECHANICAL PERMEABILITY; METABOLISM; MICROFLUIDICS; PHYSIOLOGY;

ALTERNATIVE METHODS; CACO-2; IN-VITRO; MICRO FLUIDIC BIOCHIPS; PARACETAMOL; PHARMACOKINETIC MODEL; PHASE II;

ESTIMATION;

PARACETAMOL; ACETAMINOPHEN SULFATE ESTER; ANALGESIC AGENT;

ANIMAL CELL; ARTICLE; BIOCHIP; BIOREACTOR; CELL ADHESION; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE CELL; INTESTINE FUNCTION; INTESTINE METABOLISM; INTRINSIC CLEARANCE; LIVER CELL; LIVER CLEARANCE; LIVER METABOLISM; MATHEMATICAL MODEL; METABOLISM; MICROFLUIDICS; NONHUMAN; RAT; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; CACO 2 CELL LINE; CELL CULTURE; EQUIPMENT DESIGN; INTESTINE; INTESTINE ABSORPTION; LIVER; MICROFLUIDIC ANALYSIS; PERMEABILITY;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANIMALS; BIOREACTORS; CACO-2 CELLS; CELLS, CULTURED; EQUIPMENT DESIGN; HUMANS; INTESTINAL ABSORPTION; INTESTINES; LIVER; MICROFLUIDIC ANALYTICAL TECHNIQUES; MODELS, BIOLOGICAL; PERMEABILITY; RATS;

EID: 84906505878     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25232     Document Type: Article

References (52)

1. Baudoin R, Griscom L, Prot JM, Legallais C, Leclerc E. 2011. Behavior of HepG2/C3A cell cultures in a microfluidic bioreactor. Biochem Eng J 53:172-181.
2. Baudoin R, Prot JM, Nicolas G, Brocheton J, Brochot C, Legallais C, Benech H, Leclerc E. 2013. Evaluation of seven drug metabolisms and clearances by cryopreserved human primary hepatocytes cultivated in microfluidic biochips. Xenobiotica 43:140-152.
3. Baudoin R, Legendre A, Jacques S, Cotton J, Bois F, Leclerc E. 2014. Evaluation of a liver microfluidic biochip to predict in vivo clearances of seven drugs in rats. J Pharm Sci 103:706-719.
4. Bayliss M, Bell J, Jenner W, Park G, Wilson K. 1999. Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. Xenobiotica 29:253-268.
5. Blaauboer BJ. 2003. The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary. Toxicol Lett 138:161-171.
6. Bouvier d'Yvoire M, Prieto P, Blaauboer BJ, Bois FY, Boobis A, Brochot C, Coecke S, Freidig A, Gundert-Remy U, Hartung T, Jacobs MN, Lavé T, Leahy DE, Lennernäs H, Loizou GD, Meek B, Pease C, Rowland M, Spendiff M, Yang J, Zeilmaker M. 2007. Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. Altern Lab Anim 35:661-671.
7. Bricks T, Paullier P, Legendre A, Fleury MJ, Zeller P, Merlier F, Anton PM, Leclerc E. Development of a new microfluidic platform integrating coculture of intestinal and hepatic cells to investigate first pass and liver metabolism of xenobiotics. Toxicology In Vitro in press doi:
8. Carlile D, Katayoun Z, Houston B. 1997. Scaling factors to related drug metabolic clearance in hepatic microsomes, isolated hepatocytes and the intact liver. Drug Metab Dispos 25:903-911.
9. Chalasani N, Gorski JC, Patel NH, Hall SD, Galinsky RE. 2002. Reply to Rostami-Hodjegan and Tucker 2002. Hepatology 35:1549-1550.
10. Choucha-Snouber L, Aninat C, Grsicom L, Madalinski G, Brochot C, Poleni PE, Razan F, Guillouzo CG, Legallais C, Corlu A, Leclerc E. 2013. Investigation of ifosfamide nephrotoxicity induced in a liver kidney co-culture biochip. Biotechnol Bioeng 110:597-608.
11. Choucha Snouber L, Letourneur F, Chafey P, Broussard C, Monge M, Legallais C, Leclerc E. 2012. Analysis of transcriptomic and proteomic profiles demonstrates the improvement of the MDCK cell function in a renal microfluidic biochip. Biotechnol Prog 28:474-484.
12. Court M, Duan S, Von Moltke L, Greenblatt D, Patten C, Miners J, Mackenzie P. 2001. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: Identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998-1006.
13. Cubitt H, Houston B, Galetin A. 2011. Prediction of human drug clearance by multiple metabolic pathways: Integration of hepatic and intestinal microsomal and cytosolic data. Drug Metab Dispos 39:864-873.
14. Geenen S, Yates J, Kenna G, Bois F, Wilson I, Westerhoff H. 2013. Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and the potential glutathionedepletion biomarkers ophthalmic acid and 5-oxoproline in humans and rats. Integr Biol 5:877-888.
15. Gertz M, Harrison A, Houston B, Galetin A. 2010. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
16. Gonçalves E, Bucher J, Ryll A, Niklas J, Mauch K, Klamt S, Rocha M, Saez-Rodriguez J. 2013. Bridging the layers: Towards integration of signal transduction, regulation and metabolism into mathematical models. Mol BioSyst 9:1576-1583.
17. Granger DN, Richardson PD, Kvietys PR, Mortillaro NA. 1980. Intestinal blood flow. Gastroenterology 78:837-863.
18. Huh D, Matthews B, Mammoto A, Montoya Zavala M, Hsin HY, Ingber D. 2010. Reconstituting organ-level lung functions on a chip. Science 328:1662-1668.
19. Ierapetritou M, Georgopoulos P, Roth C, Androulakis I. 2009. Tissue-level modeling of xenobiotic metabolism in liver: An emerging tool for enabling clinical translational research. Clin Transl Sci 2:228-237.
20. Imura Y, Asana Y, Sata K, Yoshimura E. 2009. A microfluidic system to evaluate intestinal absorption. Anal Sci 25:1403-1407.
21. Ito K, Houston JB. 2004. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 21:785-792.
22. Kadono K, Akabane T, Tabata K, Gato K, Terashita S, Teramura T. 2010. Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab Dispos 38:1230-1237.
23. Kimura H, Nakayama H, Yamamoto T, Sakai Y, Fujii T. 2009. Development of On chip co culture system for cytotoxicity test using Caco-2 and HepG2. IEEJ 1:252-258.
24. Legendre A, Baudoin R, Alberto G, Paullier P, Naudot M, Bricks T, Brocheton J, Jacques S, Cotton J, Leclerc E. 2013. Metabolic characterization of primary rat hepatocytes cultivated in parallel microfluidic biochips. J Pharm Sci 102:3264-3276.
25. Lin J, Chiba M, Baillie T. 1999. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-157.
26. Naritomi Y, Terashita S, Kagayama A, Sugiyama Y. 2003. Utility of hepatocytes in predicting drug metabolism: Comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31:580-588.
27. Novik E, Maguire TJ, Chao P, Cheng KC, Yarmush ML. 2010. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol 79:1036-1044.
28. Mahler GJ, Esch MB, Glahn RP, Shuler ML. 2009. Characterization of a gastrointestinal tract microscale cell culture analog used to predict drug toxicity. Biotechnol Bioeng 104:193-205.
29. Mahler GJ, Esch MB, Elad T, Southard T, Archer S, Glahn RP, Shuler ML. 2012. Oral exposure to polystyrene nanoparticles affects iron absorption. Nat Nanotechnol 7:257-263.
30. Marino A, Yarde M, Patel H. 2005. Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. Int J Pharm 297:235-241.
31. Midwoud PM, van Groothuis GMM, Merema MT, Verpoorte E. 2010a. Microfluidic biochip for the perifusion of precision-cut rat liver slices for metabolism and toxicology studies. Biotechnol Bioeng 105:184-194.
32. Midwoud PM, van Merema MT, Verpoorte E, Groothuis GMM. 2010b. A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. Lab Chip 10:2778-2786.
33. Obach RS, Lombardo F, Waters NJ. 2008. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. DMD 36(7):1385-1405.
34. Pang S, Rowland M. 1977a. Hepatic clearance of drugs. 1. Theoretical considerations of a well-stirred model and a parallel tube model-Influence of hepatic blood-flow, plasma and blood-cell binding, and hepatocellular enzymatic-activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653.
35. Pang S, Rowland M. 1977b. Hepatic clearance of drugs. 2. Experimental-evidence for acceptance of well-stirred model over parallel tube model using lidocaine in perfused rat-liver in situ preparation. J Pharmacokinet Biopharm 5:655-680.
36. Pollack GM, Brouwer KLR, Demby KB, Jones JA. 1990. Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green and galactose. Drug Metab Dispos 18:197-202.
37. Raeissi SD, Guo Z, Dobson GL, Artursson P, Hidalgo IJ. 1997. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine. Pharm Res 14:1019-1025.
38. Ramello C, Paullier P, Ould Dris A, Monge M, Legallais C, Leclerc E. 2011. Investigation into modification of mass transfer kinetics by acrolein in a renal biochip. Toxicol In Vitro 25:1123-1131.
39. Riley RJ, McGinnity DF, Austin RP. 2005. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. DMD 33(9):1304-1311.
40. Reith D, Medlicott NJ, Kumara De Silva R, Yang L, Hickling J, Zacharias M. 2009. Simultaneous modelling of the Michaelis-Menten kinetics of paracetamol sulphation and glucuronidation. Clin Exp Pharmacol Physiol 36:35-42.
41. Roberts MS, Rowland M. 1986. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J Pharmacokinet Biopharm 14(3):227-260.
42. Rostami-Hodjegan A, Tucker G. 2004. In silico simulations to assess the in vivo consequences of in vitro metabolic drug-drug interactions. Drug Discov Today 1:441-448.
43. Siissalo S, Laine L, Tolonen A, Kaukonen A, Finel M, Hirvonen J. 2010. Caco-2 cell monolayers as a tool to study simultaneous phase II metabolism and metabolite efflux of indomethacin, paracetamol and 1-naphthol. Int J Pharm 383:24-29.
44. Takahashi M, Washio T, Suzuki N, Igeta K, Yamashita S. 2009. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. J Pharm Sci 98:4343-4353.
45. Takahashi M, Washio T, Suzuki N, Igeta K, Yamashita S. 2010. Investigation of the intestinal permeability and first-pass metabolism of drugs in cynomolgus monkeys using single-pass intestinal perfusion. Biol Pharm Bull 33:111-116.
46. Sung JH, Kam C, Shuler MJ. 2010. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 10:446-455.
47. Viravaidya K, Shuler ML. 2004. Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. Biotechnol Prog 20:590-597.
48. Wu B, Kulkarni K, Basu S, Zhang S, Hu M. 2011. First-pass metabolism via UDP glucuronosyltransferase: A barrier to oral bioavailability of phenolics. J Pharm Sci 100:3655-3681.
49. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. 2007. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684.
50. Zhang C, Zhao Z, Abdul Rahim N, van Noort D, Yu H. 2009. Towards a human-on-chip: Culturing multiple cell types on a chip with compartmentalized microenvironments. Lab chip 9:3165-3312.
51. Zeman F, Fkaizki M. 1977. Protein, dipeptide, and amino acid absorption in the young of protein-deprived rats. Pediatr Res 11:972-977.
52. Zuegge J, Schneider G, Coassolo P, Lave T. 2001. Prediction of hepatic metabolic clearance - Comparison and assessment of prediction models. Clin Pharmacokinet 40:553-563.